D5B
D5B is a potent and selective PD-L1 inhibitor. D5B has been modified by DBCO. The EC50 of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity[1].
Product Specifications
UNSPSC
12352005
Target
PD-1/PD-L1
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/d5b.html
Smiles
O=C(CCC(N1CC2=CC=CC=C2C#CC3=C1C=CC=C3)=O)OCCOCCOCCOCCOCCOC([C@H]4N(CC5=C(OC)C=C(OCC6=CC=CC(C7=CC=CC=C7)=C6C)C=C5OC)CCCC4)=O
Molecular Formula
C58H66N2O12
Molecular Weight
983.15
References & Citations
[1]Hou B, et al. Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy. Sci Adv. 2024 Nov 15;10 (46) :eadq3940.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470009-100 1x 100 µL
MART-1 / Melan-A (M2-7C10), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470745-500 1x 500 µL
CD45 / LCA (2B11 + PD7/26), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC051037-500 1x 500 µL
CD44 Standard (DF1485), CF405M conjugate, 0.1mg/mL
Sign In for Pricing
View Details 